Oncternal Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2000
Net Income	-36.38	-39.48	-44.17	-31.33	-17.23	-34.19	Upgrade
Depreciation & Amortization	0.17	0.17	0.18	0.17	0.15	0.09	Upgrade
Share-Based Compensation	6.98	7.5	7.43	5.88	1.56	0.51	Upgrade
Other Operating Activities	0.6	-0.36	-0.14	-1.3	-1.98	16.84	Upgrade
Operating Cash Flow	-28.63	-32.16	-36.7	-26.59	-17.5	-16.75	Upgrade
Acquisitions	0	0	0	0	0	18.29	Upgrade
Change in Investments	23.92	0.65	-26.5	0	0	0	Upgrade
Other Investing Activities	-	-	-	-	-	-2.16	Upgrade
Investing Cash Flow	23.92	0.65	-26.5	0	0	16.14	Upgrade
Share Issuance / Repurchase	-0.14	1.07	9.58	0.62	113.88	0.02	Upgrade
Debt Issued / Paid	0	0	0	0	0.3	0	Upgrade
Financing Cash Flow	-0.14	1.07	9.58	0.62	114.18	0.02	Upgrade
Net Cash Flow	-4.85	-30.45	-53.62	-25.97	96.69	-0.59	Upgrade
Free Cash Flow	-28.63	-32.16	-36.7	-26.59	-17.5	-16.75	Upgrade
Free Cash Flow Margin	-2487.66%	-4097.32%	-2463.36%	-616.20%	-518.37%	-690.56%	Upgrade
Free Cash Flow Per Share	-9.68	-10.94	-13.96	-10.78	-17.23	-32.42	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).